RELMADA THERAPEUTICS, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Relmada Therapeutics, Inc. (RLMD) on August 29, 2025. The company is incorporated in Nevada and its common stock trades on the NASDAQ Capital Market. The report discloses a specific transaction under Item 7.01 (Regulation FD Disclosure).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a specific insider transaction and does not contain financial statements or performance metrics.
Material Changes
The material event reported is the open market purchase of 55,000 shares of the Company's common stock by Raj S. Pruthi, MD, the Chief Medical Officer-Urology. This transaction occurred on August 29, 2025.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. The information provided is strictly factual regarding the share purchase and includes a standard disclaimer that the content is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Key Facts for Investor Verification
- Insider Transaction: Raj S. Pruthi, MD (Chief Medical Officer-Urology) purchased 55,000 shares of common stock.
- Transaction Date: August 29, 2025.
- Transaction Type: Open market purchase.
- Stock Details: Common stock, $0.001 par value per share, trading symbol RLMD.
- Financial Data: No financial performance data is included in this specific filing.